Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Two-Part, Open-Label, Fixed-Sequence, Safety, Tolerability and Drug-Drug Interaction Study Between Single Dose Erenumab or Galcanezumab and Multiple Dose Ubrogepant in Participants With Migraine

Next Previous
Trial Profile

A Phase 1b, Two-Part, Open-Label, Fixed-Sequence, Safety, Tolerability and Drug-Drug Interaction Study Between Single Dose Erenumab or Galcanezumab and Multiple Dose Ubrogepant in Participants With Migraine

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubrogepant (Primary) ; Erenumab; Galcanezumab
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Allergan

Most Recent Events

  • 05 Apr 2021 Primary endpoint (Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab) , has been met according to Results published in the Headache
  • 05 Apr 2021 Primary endpoint (Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab) , has been met according to Results published in the Headache
  • 05 Apr 2021 Primary endpoint (Part 2: AUC0- for Ubrogepant Alone and in Combination With Galcanezumab) , has been met according to Results published in the Headache

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top